Remibrutinib Cuts Multiple Sclerosis Relapse Rates in Phase III Trials

(MedPage Today) -- Twice daily oral doses of 100 mg of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib reduced relapses more than teriflunomide (Aubagio) in patients with relapsing multiple sclerosis (MS), data from two identical phase...

Read it at MedPage Today ↗

← Front page